End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.44 EUR | +2.49% |
|
+2.49% | -10.19% |
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.19% | 17.33B | - | ||
-3.18% | 185B | C+ | ||
-2.68% | 105B | C | ||
-2.23% | 68.9B | A | ||
-6.46% | 46.16B | B- | ||
+5.33% | 40.75B | B+ | ||
+20.09% | 31.11B | B | ||
+11.34% | 24.26B | A- | ||
-6.67% | 23.94B | A- | ||
-12.70% | 21.86B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAX Stock
- 4BAX Stock
- Ratings Baxter International Inc.